Clinical Data and Medicus Middleware Announce Availability of Chameleon Middleware System for Medical Labs in U.S.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) and Medicus Middleware, Inc. today announced the availability of the Chameleon[TM] Middleware System for medical laboratories in the United States. Chameleon is an exclusive product of Clinical Data Sales & Service, Inc. (CDSS) that allows laboratories to connect multiple analyzers to a single LIS/EMR interface. Chameleon includes a powerful, rule-based auto validation system that is designed to be simple for the user to manage. Rules can be added or changed at any time by simply having the user select parameters from a menu of choices. This enables the laboratory to increase result throughput, vastly improve operator efficiency, and decrease overall turnaround time.

Ronald J. Rossman, President of Medicus Middleware Systems, said, "Developed from the ground up as a middleware system, Chameleon is the next evolutionary step in laboratory data workflow management."

Gus Gardner, President of CDSS, commented, "This agreement gives us a powerful, low-cost data management solution for our distribution partners and their customers in the physician office lab and small clinical lab testing markets. Chameleon allows lab data to become EMR information in a seamless, hands-off tool. This allows the lab to focus on best practices without the diversion of the typical technical and data challenges."

Chameleon comes standard with six preprogrammed analyzer interfaces and an embedded LIS/EMR interface, a full QC management system, cumulative patient results storage, communication logging, automatic data traceability, CLIA compliant reports and a failsafe data buffering system designed to protect critical data transmissions from connection interruptions. Chameleon's interface engine has built in real time communication diagnostics and can operate in several modes from fully automatic pass through of results to completely manual validation of all results. The Chameleon interface engine can communicate via serial or on a network using TCP allowing for maximum configuration flexibility.

About Medicus Middleware, Inc.

Medicus Middleware, Inc has been developing OEM data systems for the medical laboratory industry since 1996 and is located in Nashville Tennessee with a satellite office in Thibodaux Louisiana. Medicus Middleware currently has over 700 systems in the field in the U.S and Europe.

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth[TM]; Cogenics[TM]; and Vital Diagnostics[TM]. The Pharmacogenomics and Molecular Services[TM] division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics[TM], in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, and Italy.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com